3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
11
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Neoplasms
2
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Meningioma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
19
Radiosurgery
16
Radiotherapy
14
Specimen Handling
11
Pemetrexed
8
Paclitaxel
6
Erlotinib Hydrochloride
6
Docetaxel
6
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Temozolomide
4
Spinal Puncture
4
Cisplatin
4
osimertinib
3
Taxes
3
Nivolumab
3
Gemcitabine
3
Gefitinib
3
Filgrastim
3
Drug Therapy
3
trametinib
2
selpercatinib
2
sapanisertib
2
motexafin gadolinium
2
epothilone B
2
dabrafenib
2
X-Rays
2
Vorinostat
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Hematologic Tests
×
CNS
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled